Pancreatic Cancer Research

ResearcherCold Spring Harbor LaboratoryActive in the last 2 years

Adrian R. Krainer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9024-9501; OpenAlex author ID A5113482239; NIH RePORTER profile ID 1859429. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 6)
Trials
0
Grants
1
Labs led
1
Collaborators
26
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 4 papers, 1 grant

Papers 9

  1. Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. Last author DOI 10.1016/j.molcel.2025.12.004↗
  2. ASO-based PKM splice-switching therapy increases anti-CTLA-4 antibody efficacy in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41421-026-00882-9↗
  3. MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-25-1104↗
  4. The Spliceosome Scaffold Component BCAS2 Promotes Pancreatic Cancer Progression through Weak 5′ Splice Site–Dependent Splicing Regulation Last author DOI 10.64898/2026.10.06.757127↗
  5. Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-024-01790-y↗
  6. Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids. Last author DOI 10.1089/nat.2023.0070↗
  7. RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05820-3↗
  8. Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-22-1013↗
  9. Loss of KRAS G12D feedback regulation involving splicing factor SRSF1 accelerates pancreatic cancer Last author DOI 10.1101/2021.10.13.464210↗

Grants 1

  1. Project 2: Splicing Dysregulation in Cancer P01CA013106↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ledong Wan · 7 shared papers, 2021–2026 · strength 1.67
  2. Alexander J. Kral · 4 shared papers, 2024–2026 · strength 1.19
  3. Christopher R. Vakoc · 1 shared paper, 1 shared grant, 2024–2026 · strength 1.03
  4. Camila dos Santos · 1 shared paper, 1 shared grant, 2024–2026 · strength 1.03
  5. David L Spector · 1 shared paper, 1 shared grant, 2024–2026 · strength 1.03
  6. Youngkyu Park · 3 shared papers, 2021–2026 · strength 0.61
  7. David Arthur Tuveson · 3 shared papers, 2021–2026 · strength 0.61
  8. Dillon Matthew Voss · 2 shared papers, 2024–2026 · strength 0.51
  9. Zhikai Wang · 2 shared papers, 2021–2023 · strength 0.32
  10. Benteng Ma · 1 shared paper, 2026 · strength 0.29
  11. Lijie Han · 1 shared paper, 2026 · strength 0.28
  12. Hao Chen · 1 shared paper, 2026 · strength 0.28
  13. Damianos S. Skopelitis · 1 shared paper, 2024 · strength 0.16
  14. Mikala Egeblad · 1 shared paper, 2024 · strength 0.16
  15. Yunus Sahin · 1 shared paper, 2024 · strength 0.16
  16. Douglas T. Fearon · 1 shared paper, 2024 · strength 0.16
  17. Philip Moresco · 1 shared paper, 2024 · strength 0.16
  18. Diogo Maia-Silva · 1 shared paper, 2024 · strength 0.16
  19. Patrick Cunniff · 1 shared paper, 2024 · strength 0.16
  20. Ela Elyada · 1 shared paper, 2023 · strength 0.14
  21. Talia Golan · 1 shared paper, 2023 · strength 0.14
  22. Lewis C. Cantley · 1 shared paper, 2023 · strength 0.14
  23. Amina Jbara · 1 shared paper, 2023 · strength 0.14
  24. Chani Stossel · 1 shared paper, 2023 · strength 0.14
  25. Rotem Karni · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.